MAXHEALTH - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.4
| Stock Code | MAXHEALTH | Market Cap | 98,428 Cr. | Current Price | 1,012 ₹ | High / Low | 1,314 ₹ |
| Stock P/E | 140 | Book Value | 87.3 ₹ | Dividend Yield | 0.15 % | ROCE | 12.5 % |
| ROE | 9.45 % | Face Value | 10.0 ₹ | DMA 50 | 1,004 ₹ | DMA 200 | 1,062 ₹ |
| Chg in FII Hold | -5.16 % | Chg in DII Hold | 5.12 % | PAT Qtr | 200 Cr. | PAT Prev Qtr | 160 Cr. |
| RSI | 56.1 | MACD | 4.36 | Volume | 26,94,459 | Avg Vol 1Wk | 20,30,639 |
| Low price | 903 ₹ | High price | 1,314 ₹ | PEG Ratio | 4.43 | Debt to equity | 0.08 |
| 52w Index | 26.4 % | Qtr Profit Var | 5.45 % | EPS | 7.10 ₹ | Industry PE | 48.2 |
Analysis: Max Healthcare is trading at 1,012 ₹, near its 50 DMA (1,004 ₹) but below its 200 DMA (1,062 ₹), showing short-term support but medium-term resistance. RSI at 56.1 and MACD at 4.36 indicate mild bullish momentum. The stock is far below its 52-week high of 1,314 ₹, leaving room for recovery. Valuation is stretched with a P/E of 140 compared to the industry average of 48.2, while ROCE (12.5%) and ROE (9.45%) remain modest. Quarterly PAT growth (200 Cr vs 160 Cr) and EPS at 7.10 ₹ show improvement, but the PEG ratio of 4.43 suggests poor valuation relative to growth. Institutional activity is mixed, with FIIs reducing holdings (-5.16%) while DIIs increased (+5.12%), balancing sentiment. Debt levels are low (0.08), providing financial stability.
Optimal Entry Price: Around 990–1,000 ₹ (near 50 DMA support zone).
Exit Strategy: If already holding, consider exiting near 1,060–1,080 ₹ (DMA 200 resistance zone) or if RSI approaches 65–70. A stop-loss can be placed around 970 ₹ to manage downside risk.
✅ Positive
- Quarterly PAT growth (200 Cr vs 160 Cr).
- EPS at 7.10 ₹, reflecting earnings improvement.
- DII holdings increased (+5.12%), showing strong domestic institutional support.
- Debt-to-equity ratio at 0.08, indicating low leverage.
⚠️ Limitation
- High P/E ratio (140) compared to industry average.
- PEG ratio at 4.43, suggesting poor valuation relative to growth.
- ROCE (12.5%) and ROE (9.45%) remain modest.
- Stock trading below 200 DMA, showing medium-term weakness.
📉 Company Negative News
- FII holdings decreased significantly (-5.16%).
- Stock trading far below 52-week high (1,314 ₹).
📈 Company Positive News
- Quarterly profit growth of 5.45% variation.
- DII holdings increased (+5.12%), boosting sentiment.
- Volume higher than weekly average, showing short-term interest.
🏭 Industry
- Industry P/E at 48.2, much lower than Max Healthcare, highlighting overvaluation.
- Healthcare sector remains resilient with steady demand and long-term growth prospects.
🔎 Conclusion
Max Healthcare is a moderately suitable candidate for swing trading, supported by earnings growth and strong DII support. Entry near 990–1,000 ₹ is optimal, with exit around 1,060–1,080 ₹. Risk management is essential due to stretched valuations, reduced FII confidence, and resistance at the 200 DMA.